700 Stock Overview
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Certara, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.80 |
| 52 Week High | US$22.60 |
| 52 Week Low | US$12.80 |
| Beta | 1.64 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -20.99% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 700 | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | -0.5% |
| 1Y | -21.0% | -24.7% | 2.5% |
Return vs Industry: 700 underperformed the German Healthcare Services industry which returned -5.5% over the past year.
Return vs Market: 700 underperformed the German Market which returned -2% over the past year.
Price Volatility
| 700 volatility | |
|---|---|
| 700 Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 3.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 700 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 700's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,177 | Bill Feehery | www.certara.com |
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers’ new drugs through the regulatory submission process and into the market.
Certara, Inc. Fundamentals Summary
| 700 fundamental statistics | |
|---|---|
| Market cap | €2.36b |
| Earnings (TTM) | -€31.07m |
| Revenue (TTM) | €325.18m |
7.3x
P/S Ratio-75.9x
P/E RatioIs 700 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 700 income statement (TTM) | |
|---|---|
| Revenue | US$352.96m |
| Cost of Revenue | US$138.74m |
| Gross Profit | US$214.22m |
| Other Expenses | US$247.95m |
| Earnings | -US$33.73m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 60.69% |
| Net Profit Margin | -9.56% |
| Debt/Equity Ratio | 27.7% |
How did 700 perform over the long term?
See historical performance and comparison